Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial. 

 This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content will be available here soon. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL